Ranibizumab biosimilar achieves similar results in patients with polypoidal choroidal vasculopathy

Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.

POLL: Will you use biosimilars in your ophthalmic practice?

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Ranibizumab biosimilar to launch in US

Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.